What question did this study set out to answer?

To review the capabilities, mechanisms, and clinical utility of CRISPR/Cas-based biosensing platforms for identifying tumor-associated genetic materials.

October 2, 2025Bioanalysis

CRISPR-based platforms for detecting tumor-associated genetic materials in clinical samples

View Full Paper

Ask AI

Bookmark

Authors

XCXiaoqing Chen QYQiaoyuan Ye QLQingle Liang

Discussion

Member takes

Overview

Narrative review highlights advances in CRISPR-based detection of diverse cancer biomarkers, suggesting new pathways for rapid and accessible clinical tumor diagnostics.

Key Points

To review the capabilities, mechanisms, and clinical utility of CRISPR/Cas-based biosensing platforms for identifying tumor-associated genetic materials.
Synthesized recent literature on CRISPR/Cas systems engineered for cancer diagnostic applications.
Evaluated platform performance across genetic and epigenetic targets, including point mutations, methylation patterns, and non-coding RNA species.
CRISPR/Cas diagnostic systems offer high programmability, rapid reaction times, strong target specificity, and integrated signal amplification over conventional assays.
Engineered Cas systems successfully identify gene mutations, DNA methylation, microRNA, long non-coding RNA, and circular RNA in patient samples.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/6a8a6f8b755d28965dfd6954 https://doi.org/10.1080/17576180.2025.2571023

View Full Paper

Ask AI

Bookmark

October 2, 2025Bioanalysis

CRISPR-based platforms for detecting tumor-associated genetic materials in clinical samples

View Full Paper

Ask AI

Bookmark

Authors

XCXiaoqing Chen QYQiaoyuan Ye QLQingle Liang

Discussion

Member takes

Overview

Narrative review highlights advances in CRISPR-based detection of diverse cancer biomarkers, suggesting new pathways for rapid and accessible clinical tumor diagnostics.

Key Points

To review the capabilities, mechanisms, and clinical utility of CRISPR/Cas-based biosensing platforms for identifying tumor-associated genetic materials.
Synthesized recent literature on CRISPR/Cas systems engineered for cancer diagnostic applications.
Evaluated platform performance across genetic and epigenetic targets, including point mutations, methylation patterns, and non-coding RNA species.
CRISPR/Cas diagnostic systems offer high programmability, rapid reaction times, strong target specificity, and integrated signal amplification over conventional assays.
Engineered Cas systems successfully identify gene mutations, DNA methylation, microRNA, long non-coding RNA, and circular RNA in patient samples.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/6a8a6f8b755d28965dfd6954 https://doi.org/10.1080/17576180.2025.2571023

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark